Program
LYB004
A development code. Also written as “Low dose antigen and low dose adjuvant of LYB004”, “Low dose antigen and high dose adjuvant of LYB004” and “High dose antigen and low dose adjuvant of LYB004”.
Its studies are mostly in Herpes Zoster, led by Guangzhou Patronus Biotech.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Guangzhou Patronus Biotech | 33 open or running | phase 2since Dec 16, 2025 | Mar 13, 2024 | none ahead |
Also a collaborator on its studies: yantai-patronus-biotech-co-ltd.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 13, 2024First study: phase 1 study in Herpes ZosterFirst studyNCT06335849 · 48 enrolled · Australia
- Mar 3, 2025Phase 1 study in Herpes ZosterNCT06874842 · 92 planned · China
- Dec 16, 2025Phase 2 study in Herpes ZosterPhase 2 reachedNCT07311148 · 840 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07311148Herpes Zoster · China | 2 | Active, not recruiting | Jan 2026 | 840 |
| NCT06874842Herpes Zoster · China | 1 | Recruiting | Feb 2026 | 92 |
| NCT06335849Herpes Zoster · Australia | 1 | Active, not recruiting | Sep 30, 2025 | 48 |
How it is read
Names in the registry
- “Low dose antigen and low dose adjuvant of LYB004”, 2 entries
- “Low dose antigen and high dose adjuvant of LYB004”, 2 entries
- “High dose antigen and low dose adjuvant of LYB004”, 2 entries
- “High dose antigen and high dose adjuvant of LYB004”, 2 entries
- “LYB004 25µg”, 1 entry
Codes read as this program: LYB004.
Conditions, from the studies’ own filings
- Herpes Zoster, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.